Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) (NCT06295367)
Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, income and insurance. Financial hardship can lead to a delay or a stop in cancer care, and is linked to poor quality of life. Financial navigation programs, such as CostCOM, provide financial counseling, education and connections to appropriate resources to reduce financial barriers to healthcare and minimize financial stress and burden. CostCOM may improve adherence to care and decrease financial burden in patients with cancer.
Who can join: Review the eligibility criteria below.
Location: Anchorage Associates in Radiation Medicine — Anchorage, Alaska
🧪 Interventions in This Study
- Best Practice (OTHER)
- Financial Navigation (OTHER)
- Interview (OTHER)
- Survey Administration (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (391 Sites)
Showing the first 25 of 391 sites.
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
- Alaska Women's Cancer Care — Anchorage, Alaska
- Katmai Oncology Group — Anchorage, Alaska
- Providence Alaska Medical Center — Anchorage, Alaska
- Fairbanks Memorial Hospital — Fairbanks, Alaska
- Kingman Regional Medical Center — Kingman, Arizona
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
- CARTI Cancer Center — Little Rock, Arkansas
- PCR Oncology — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Contra Costa Regional Medical Center — Martinez, California
- Providence Queen of The Valley — Napa, California
- Providence Medical Foundation - Santa Rosa — Santa Rosa, California
- Providence Santa Rosa Memorial Hospital — Santa Rosa, California
- BASS Medical Group - Lennon — Walnut Creek, California
- Rocky Mountain Cancer Centers-Aurora — Aurora, Colorado
- Boulder Community Foothills Hospital — Boulder, Colorado
- Rocky Mountain Cancer Centers-Boulder — Boulder, Colorado
- Rocky Mountain Cancer Centers - Centennial — Centennial, Colorado
- The Women's Imaging Center — Denver, Colorado
- Colorado Blood Cancer Institute — Denver, Colorado
- Presbyterian - Saint Lukes Medical Center - Health One — Denver, Colorado
📞 Contact the Study Coordinator
Phone: (907) 212-6871
Email: AKPAMC.OncologyResearchSupport@providence.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Malignant Solid Neoplasm
- Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) — Philadelphia, Pennsylvania
- Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors — Birmingham, Alabama
- Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) — Philadelphia, Pennsylvania
- Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial — Birmingham, Alabama
- Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial — Bethesda, Maryland
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) — Philadelphia, Pennsylvania
Explore by condition: All Malignant Solid Neoplasm clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.